Complementary and alternative medicine approaches to blood pressure reduction: An evidence-based review

Canadian Family Physician

Volumn 54, Issue 11, 2008, Pages 1529-1533

  Nahas, Richard ^a  

^a Seekers Centre for Integrative Medicine   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; COLECALCIFEROL; FLAVONOID; MELATONIN; PLACEBO; UBIDECARENONE; UBIQUINONE; VITAMIN D;

ACUPUNCTURE; BREATHING PATTERN; CACAO; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; MEDITATION; REVIEW; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

CACAO; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; HUMANS; HYPERTENSION; MICRONUTRIENTS;

EID: 56549103740     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-52.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-52. Epub 2003 Dec 1.
3. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, et al. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA 2002;288(15):1882-8.
4. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993;328(4):246-52.
5. McFarland B, Bigelow D, Zani B, Newsom J, Kaplan M. Complementary and alternative medicine use in Canada and the United States. Am J Public Health 2002;92(10):1616-8.
6. Barnes P, Powell-Griner E, McFann K, Nahin R. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004;(343):1-19.
7. Hollenberg NK, Schmitz H, Macdonald I, Poulter N. Cocoa, flavanols and cardiovascular risk. Br J Cardiol 2004;11(5):379-86.
8. Buijsse B, Feskens EJM, Kok FJ, Kromhout D. Cocoa intake, blood pressure, and cardiovascular mortality: the Zutphen Elderly Study. Arch Intern Med 2006;166(4):411-7.
9. Taubert D, Roesen R, Schomig E. Effect of cocoa and tea intake on blood pressure. Arch Intern Med 2007;167(7):626-34.
10. Taubert D, Roesen R, Lehmann C, Jung N, Schomig E. Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide. JAMA 2007;298(1):49-60.
11. Foster MW, Pawloski JR, Singel DJ, Stamler JS. Role of circulating S-nitrosothiols in control of blood pressure. Hypertension 2005;45(1):15-7. Epub 2004 Nov 22.
12. Engler MB, Engler MM, Chen CY, Malloy MJ, Browne A, Chiu EY, et al. Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentration in healthy adults. J Am Coll Nutr 2004;23(3):197-204.
13. Balzer J, Rassaf T, Heiss C, Kleinbongard P, Lauer T, Merx M, et al. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients: a double-masked, randomized, controlled trial. J Am Coll Cardiol 2008;51(22):2141-9.
14. Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S. Coenzyme Q10 in health and disease. Eur J Clin Nutr 1999;53(10):764-70.
15. Sugiyama S, Kitazawa M, Ozawa T, Suzuki K, Izawa Y. Anti-oxidative effect of coenzyme Q10. Experentia 1980;36(8):1002-3.
16. Bonakdar A, Guarnieri E. Coenzyme Q10. Am Fam Physician 2005;72(6):1065-70.
17. Jula A, Marniemi J, Huupponen R, Virtanen A, Rastas M, Ronnemaa T. Effects of diet and simvastatin on serum lipids, insulin and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 2002;287(5):598-605.
18. Yamagami T, Shibata N. Bioenergetics in clinical medicine: studies on coenzyme Q10 and essential hypertension. Res Commun Chem Pathol Pharmacol 1975;11(2):273-88.
19. Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong J-Y, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens 2007;21(4):297-306. Epub 2007 Feb 8.
20. Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994;15(Suppl):S287-94.
21. Brzezinski A. Melatonin in humans. N Engl J Med 1997;336(3):186-95.
22. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev 2002;2:CD001520.
23. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood pressure. Lancet 1978;311(8068):795-7.
24. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989;79(4):733-43.
25. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999;282(6):539-46.
26. Brugger P, Marktl W, Herold M. Impaired secretion of melatonin in coronary heart disease. Lancet 1995;345(8962):1408.
27. Shaw JA, Chin-Dusting JP, Kingwell BA, Dart AM. Diurnal variation in endothelium-dependent vasodilation is not apparent in coronary artery disease. Circulation 2001;103(6):806-12.
28. Cagnacci A, Cannoletta M, Renzi A, Baldassari F, Arangino S, Volpe A. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am J Hypertens 2005;18(12 Pt 1):1614-8.
29. Scheer FAJL, Van Montfrans GA, van Someren EJW, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004;43(2):192-7. Epub 2004 Jan 19.
30. Lusardi P, Piazza E, Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. Br J Clin Pharmacol 2000;49(5):423-7.
31. Rommel T, Demish L. Influence of chronic beta-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension. J Neural Transm Gen Sect 1994;95(1):39-48.
32. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357(3):266-81.
33. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110(2):229-38.
34. Carthy EP, Yamashita W, Hsu A, Ooi BS. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension 1989;13(6 Pt 2):954-9.
35. Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997;30(2 Pt 1):150-6.
36. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007;49(5):1063-9.
37. Giovannucci E, Liu Y, Holis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men. Arch Intern Med 2008;168(11):1174-80.
38. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001;86(4):1633-7.
39. Vieth R. Why the optimal requirement for vitamin D3 is probably much higher than what is officially recommended for adults. J Steroid Biochem Mol Biol 2004;89-90(1-5):575-9.
40. Lee MS, Pittler MH, Guo R, Ernst E. Qigong for hypertension: a systematic review of randomized clinical trials. J Hypertens 2007;25(8):1525-32.
41. Guo X, Zhou B, Nishimura T, Termukai S, Fukushima M. Clinical effect of Qigong practice on essential hypertension: a meta-analysis of randomized controlled trials. J Altern Complement Med 2008;14(1):27-37.
42. Parati G, Glavina F, Onagro G, Maronati A, Gavish B, Castiglioni P, et al. Music-guided slow breathing: acute effects on cardiovascular parameters and baroreflex sensitivity in normal subjects. J Hypertens 2002;20(Suppl):S174.
43. Brook RD, Julius S. Autonomic imbalance, hypertension, and cardiovascular risk. Am J Hypertens 2000;13(6 Pt 2):112S-22S.
44. Parati G, Carretta R. Device-guided slow breathing as a non-pharmacological approach to antihypertensive treatment: efficacy, problems and perspectives. J Hypertens 2007;25(1):57-61.
45. Canter PH, Ernst E. Insufficient evidence to conclude whether or not transcendental meditation decreases blood pressure: results of a systematic review of randomized clinical trials. J Hypertens 2004;22(11):2049-54.
46. Anderson JW, Liu C, Kryscio RJ. Blood pressure response to transcendental meditation: a meta-analysis. Am J Hypertens 2008;21(3):310-6. Epub 2008 Jan 31.
47. World Health Organization. Guidelines for clinical research in acupuncture. Western Pacific series no. 15. Manila, Philippines: WHO Regional Office for the Western Pacific; 1995.
48. Yin CS, Seo BK, Park HJ, Lim S, Cho M, Jung WS, et al. Acupuncture, a promising adjunctive therapy for essential hypertension: a double-blind, randomized, controlled trial. Neurologic Res 2007;29(Suppl 1):S98-103.
49. Macklin EA, Wayne PM, Kalish LA, Valaskatgis P, Thompson J, Pian-Smith MCM, et al. Stop Hypertension With the Acupuncture Research Program (SHARP). Hypertension 2006;48(5):838-45. Epub 2006 Oct 2.